Free Trial

OnKure Therapeutics (OKUR) Competitors

OnKure Therapeutics logo
$2.69 -0.14 (-4.95%)
Closing price 09/4/2025 04:00 PM Eastern
Extended Trading
$2.64 -0.04 (-1.67%)
As of 09/4/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OKUR vs. CLLS, CRDF, FBRX, HURA, CHRS, BHST, IKT, ACOG, ZURA, and CABA

Should you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include Cellectis (CLLS), Cardiff Oncology (CRDF), Forte Biosciences (FBRX), TuHURA Biosciences (HURA), Coherus Oncology (CHRS), BioHarvest Sciences (BHST), Inhibikase Therapeutics (IKT), Alpha Cognition (ACOG), Zura Bio (ZURA), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry.

OnKure Therapeutics vs. Its Competitors

Cellectis (NASDAQ:CLLS) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

63.9% of Cellectis shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 2.3% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cellectis presently has a consensus price target of $4.00, suggesting a potential upside of 52.09%. OnKure Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 1,101.98%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Cellectis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
OnKure Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.14

OnKure Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -100.69%. OnKure Therapeutics' return on equity of -60.52% beat Cellectis' return on equity.

Company Net Margins Return on Equity Return on Assets
Cellectis-100.69% -68.05% -21.53%
OnKure Therapeutics N/A -60.52%-55.43%

Cellectis has a beta of 3.03, suggesting that its share price is 203% more volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

In the previous week, Cellectis had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 4 mentions for Cellectis and 0 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.71 beat Cellectis' score of 0.17 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cellectis Neutral
OnKure Therapeutics Positive

Cellectis has higher revenue and earnings than OnKure Therapeutics. Cellectis is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$49.22M2.97-$36.76M-$0.82-3.21
OnKure TherapeuticsN/AN/A-$52.67M-$4.80-0.56

Summary

OnKure Therapeutics beats Cellectis on 9 of the 16 factors compared between the two stocks.

Get OnKure Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OKUR vs. The Competition

MetricOnKure TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$38.29M$3.13B$5.76B$9.85B
Dividend YieldN/A2.28%6.67%4.51%
P/E Ratio-0.5620.8975.6526.43
Price / SalesN/A458.96549.99119.09
Price / CashN/A44.5237.0558.92
Price / Book0.359.9311.176.06
Net Income-$52.67M-$53.38M$3.29B$266.28M
7 Day Performance-2.18%0.63%0.18%-0.33%
1 Month Performance24.54%6.31%6.28%3.43%
1 Year PerformanceN/A11.63%55.11%23.10%

OnKure Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OKUR
OnKure Therapeutics
2.8841 of 5 stars
$2.69
-4.9%
$32.33
+1,102.0%
N/A$38.29MN/A-0.56N/AGap Down
CLLS
Cellectis
2.513 of 5 stars
$2.57
-1.2%
$4.00
+55.6%
+14.3%$143.02M$49.22M-3.13290Positive News
Short Interest ↑
CRDF
Cardiff Oncology
2.8263 of 5 stars
$2.10
+1.0%
$10.10
+381.0%
-2.7%$139.70M$680K-2.4120
FBRX
Forte Biosciences
3.3646 of 5 stars
$11.00
-2.0%
$68.00
+518.2%
+50.1%$136.76MN/A-0.685Options Volume
High Trading Volume
HURA
TuHURA Biosciences
1.4 of 5 stars
$2.70
-3.9%
$12.67
+369.1%
N/A$135.13MN/A0.00N/A
CHRS
Coherus Oncology
4.1662 of 5 stars
$1.16
-1.7%
$4.68
+303.7%
+0.0%$134.82M$266.96M0.75330Analyst Upgrade
Gap Up
BHST
BioHarvest Sciences
N/A$8.18
+2.8%
$13.67
+67.1%
N/A$134.36M$25.19M-11.69N/APositive News
Gap Down
IKT
Inhibikase Therapeutics
1.7739 of 5 stars
$1.80
-2.2%
$6.50
+261.1%
+26.7%$134.13MN/A-0.676Positive News
ACOG
Alpha Cognition
2.5061 of 5 stars
$8.30
+3.0%
$20.00
+141.0%
N/A$134.13MN/A-5.19N/APositive News
ZURA
Zura Bio
2.9121 of 5 stars
$2.04
-3.8%
$14.00
+586.3%
-47.6%$132.64MN/A-2.913News Coverage
CABA
Cabaletta Bio
2.4349 of 5 stars
$1.45
-3.3%
$14.43
+895.1%
-69.6%$132.62MN/A-0.5450News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:OKUR) was last updated on 9/5/2025 by MarketBeat.com Staff
From Our Partners